SI3782617T1 - Farmacevtski sestavki v gelu, ki vsebujejo levodopo, karbidopo in entakapon - Google Patents
Farmacevtski sestavki v gelu, ki vsebujejo levodopo, karbidopo in entakaponInfo
- Publication number
- SI3782617T1 SI3782617T1 SI201531992T SI201531992T SI3782617T1 SI 3782617 T1 SI3782617 T1 SI 3782617T1 SI 201531992 T SI201531992 T SI 201531992T SI 201531992 T SI201531992 T SI 201531992T SI 3782617 T1 SI3782617 T1 SI 3782617T1
- Authority
- SI
- Slovenia
- Prior art keywords
- entacapone
- carbidopa
- levodopa
- gel compositions
- pharmaceutical gel
- Prior art date
Links
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title 1
- 229960004205 carbidopa Drugs 0.000 title 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 title 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 title 1
- 229960003337 entacapone Drugs 0.000 title 1
- 229960004502 levodopa Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000008252 pharmaceutical gel Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1451034A SE538425C2 (en) | 2014-09-04 | 2014-09-04 | Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof |
| SE1550344 | 2015-03-24 | ||
| EP20200070.9A EP3782617B1 (en) | 2014-09-04 | 2015-09-04 | Pharmaceutical gel compositions comprising levodopa, carbidopa and entacapone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3782617T1 true SI3782617T1 (sl) | 2024-04-30 |
Family
ID=55440194
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201531474T SI3188725T1 (sl) | 2014-09-04 | 2015-09-04 | Farmacevtski sestavki, ki vsebujejo levodopo, dopamin dekarboksilazni inhibitor in COMT inhibitor in način uporabe zdravila |
| SI201531992T SI3782617T1 (sl) | 2014-09-04 | 2015-09-04 | Farmacevtski sestavki v gelu, ki vsebujejo levodopo, karbidopo in entakapon |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201531474T SI3188725T1 (sl) | 2014-09-04 | 2015-09-04 | Farmacevtski sestavki, ki vsebujejo levodopo, dopamin dekarboksilazni inhibitor in COMT inhibitor in način uporabe zdravila |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10071069B2 (sl) |
| EP (3) | EP4356907A1 (sl) |
| JP (2) | JP6622310B2 (sl) |
| CN (1) | CN107072973A (sl) |
| AU (3) | AU2015312430B2 (sl) |
| CA (2) | CA3175785A1 (sl) |
| DK (2) | DK3782617T3 (sl) |
| ES (1) | ES2844500T3 (sl) |
| FI (1) | FI3782617T3 (sl) |
| HR (2) | HRP20240314T1 (sl) |
| HU (1) | HUE052857T2 (sl) |
| PL (1) | PL3188725T3 (sl) |
| PT (2) | PT3782617T (sl) |
| RS (1) | RS65337B1 (sl) |
| SI (2) | SI3188725T1 (sl) |
| WO (1) | WO2016036308A1 (sl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3782617T3 (da) | 2014-09-04 | 2024-03-04 | Lobsor Pharmaceuticals Ab | Farmaceutiske gelsammensætninger omfattende levodopa, carbidopa og entacapon |
| JP2018500300A (ja) * | 2014-11-28 | 2018-01-11 | ノヴィファーマ，エス．アー． | パーキンソン病を遅延させるための医薬 |
| KR20180004756A (ko) | 2015-05-06 | 2018-01-12 | 신애질 코포레이션 | 약물 입자를 함유하는 제약 현탁액, 그의 투여를 위한 장치, 및 그의 사용 방법 |
| WO2017039525A1 (en) | 2015-09-04 | 2017-03-09 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| EP3442516A4 (en) * | 2016-04-11 | 2019-12-18 | University of Canberra | OPHTHALMIC COMPOSITIONS WITH LEVODOPA, AN ANTIOXIDANE AND AN AQUEOUS SUBSTANCE |
| EP3487479A1 (en) * | 2016-07-20 | 2019-05-29 | AbbVie Inc. | Levodopa and carbidopa intestinal gel and methods of use |
| EP3275433A1 (en) * | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| CA3053211A1 (en) * | 2017-02-13 | 2018-08-16 | Bayer Animal Health Gmbh | Liquid composition containing pradofloxacin and antioxidants |
| WO2019129120A1 (en) * | 2017-12-28 | 2019-07-04 | Rpxds Co., Ltd | Tolcapone for prevention and/or treatment of obesity and related metabolic diseases |
| WO2019182506A1 (en) * | 2018-03-23 | 2019-09-26 | Lobsor Pharmaceuticals Aktiebolag | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders |
| EP3593819A1 (en) | 2018-07-10 | 2020-01-15 | Medday Pharmaceuticals | Compositions for therapeutic uses containing 5-htp and carbidopa |
| CN111643493B (zh) * | 2020-05-26 | 2023-01-10 | 上海京新生物医药有限公司 | 一种高浓度左旋多巴制剂及其制备方法及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004348D0 (en) | 1990-02-27 | 1990-04-25 | Orion Yhtymae Oy | New use of catechol derivatives and their physiologically acceptable salts and esters |
| SE9203594D0 (sv) | 1992-11-30 | 1992-11-30 | Christer Nystroem | Laekemedel i dispersa system |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US20100221321A1 (en) | 2003-02-27 | 2010-09-02 | Innercap Technologies, Inc. | Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions |
| CN1845728B (zh) * | 2003-08-29 | 2013-06-19 | 转化医药公司 | 包含左旋多巴和卡比多巴的药物组合物 |
| WO2005023185A2 (en) | 2003-08-29 | 2005-03-17 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| WO2005099678A1 (en) | 2004-04-06 | 2005-10-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| US20060222703A1 (en) | 2005-04-01 | 2006-10-05 | Iprbox Oy | Pharmaceutical composition and preparation method thereof |
| CA2653683A1 (en) | 2006-05-31 | 2007-12-06 | Solvay Pharmaceuticals Gmbh | Long term 24-hour intestinal administration of levodopa/carbidopa |
| US8741342B2 (en) | 2006-10-30 | 2014-06-03 | Wockhardt Research Centre | Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa |
| NZ587168A (en) * | 2008-02-06 | 2011-06-30 | Wockhardt Research Center | Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability |
| SG10201505101VA (en) * | 2009-05-19 | 2015-07-30 | Neuroderm Ltd | Compositions For Continuous Administration Of Dopa Decarboxylase Inhibitors |
| US20130253056A1 (en) | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
| HUE037005T2 (hu) | 2010-11-15 | 2018-08-28 | Neuroderm Ltd | L-dopának, dopa dekarboxiláz inhibitoroknak, katechol-O-metil transzferáz inhibitoroknak és ezekhez szolgáló kompozícióknak folyamatos bevezetése |
| WO2012147099A1 (en) | 2011-04-25 | 2012-11-01 | Suven Nishtaa Pharma Pvt. Ltd. | Pharmaceutical compositions of levodopa, carbidopa and entacapone |
| JP6472391B2 (ja) | 2013-03-13 | 2019-02-20 | ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ | パーキンソン病の治療方法 |
| SE538425C2 (en) | 2014-09-04 | 2016-06-21 | Lobsor Pharmaceuticals Ab | Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof |
| DK3782617T3 (da) | 2014-09-04 | 2024-03-04 | Lobsor Pharmaceuticals Ab | Farmaceutiske gelsammensætninger omfattende levodopa, carbidopa og entacapon |
| WO2017039525A1 (en) | 2015-09-04 | 2017-03-09 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
-
2015
- 2015-09-04 DK DK20200070.9T patent/DK3782617T3/da active
- 2015-09-04 HR HRP20240314TT patent/HRP20240314T1/hr unknown
- 2015-09-04 EP EP23219005.8A patent/EP4356907A1/en active Pending
- 2015-09-04 US US15/507,959 patent/US10071069B2/en active Active
- 2015-09-04 CA CA3175785A patent/CA3175785A1/en active Pending
- 2015-09-04 SI SI201531474T patent/SI3188725T1/sl unknown
- 2015-09-04 JP JP2017533154A patent/JP6622310B2/ja active Active
- 2015-09-04 CN CN201580050984.7A patent/CN107072973A/zh active Pending
- 2015-09-04 SI SI201531992T patent/SI3782617T1/sl unknown
- 2015-09-04 RS RS20240276A patent/RS65337B1/sr unknown
- 2015-09-04 HU HUE15838800A patent/HUE052857T2/hu unknown
- 2015-09-04 CA CA2959307A patent/CA2959307C/en active Active
- 2015-09-04 EP EP20200070.9A patent/EP3782617B1/en active Active
- 2015-09-04 PL PL15838800T patent/PL3188725T3/pl unknown
- 2015-09-04 PT PT202000709T patent/PT3782617T/pt unknown
- 2015-09-04 AU AU2015312430A patent/AU2015312430B2/en active Active
- 2015-09-04 FI FIEP20200070.9T patent/FI3782617T3/fi not_active Application Discontinuation
- 2015-09-04 ES ES15838800T patent/ES2844500T3/es active Active
- 2015-09-04 EP EP15838800.9A patent/EP3188725B1/en active Active
- 2015-09-04 PT PT158388009T patent/PT3188725T/pt unknown
- 2015-09-04 WO PCT/SE2015/050939 patent/WO2016036308A1/en active Application Filing
- 2015-09-04 DK DK15838800.9T patent/DK3188725T3/da active
-
2018
- 2018-08-03 US US16/054,392 patent/US10786472B2/en active Active
-
2019
- 2019-11-21 JP JP2019210309A patent/JP6889231B2/ja active Active
-
2020
- 2020-08-13 US US16/992,824 patent/US11413262B2/en active Active
- 2020-09-23 AU AU2020239682A patent/AU2020239682B2/en active Active
-
2021
- 2021-01-07 HR HRP20210025TT patent/HRP20210025T1/hr unknown
-
2022
- 2022-01-18 AU AU2022200291A patent/AU2022200291B2/en active Active
- 2022-06-07 US US17/834,839 patent/US20220362193A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3782617T3 (fi) | Farmaseuttisia geelikoostumuksia, jotka käsittävät levodopaa, karbidopaa ja entakaponia | |
| EP3121241A4 (en) | Heat cycle system composition and heat cycle system | |
| ZA201803485B (en) | Pharmaceutical compositions comprising levodopa amide and uses thereof | |
| IL246987A0 (en) | Heteroaryl amides, preparations containing it and their uses | |
| IL256137B (en) | Corneal implant and its use | |
| HK1252026A1 (zh) | 藥物組合及其應用 | |
| IL287825A (en) | Structures of sirp-alpha variant and their uses | |
| IL252397A0 (en) | Pharmaceutical preparations, their preparation and uses | |
| GB201502002D0 (en) | Uses and compositions | |
| IL290114A (en) | Pharmaceutical preparations, their preparation and uses | |
| PL3229843T3 (pl) | Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji | |
| IL254241A0 (en) | Etv2 and its uses | |
| IL253487A0 (en) | Levodopa and carbidopa intestinal coagulant and methods of use | |
| HK1250915A1 (zh) | 組合物和其用途 | |
| GB201502026D0 (en) | Uses and compositions | |
| GB201501991D0 (en) | Uses and compositions | |
| IL259217A (en) | The composition of a sealant and its uses | |
| IL248863A0 (en) | Preparations containing il-31 and their use | |
| IL255024A0 (en) | Hydroxamic acids and their uses | |
| DK3145548T3 (en) | Aqueous gel composition and its use | |
| GB201522814D0 (en) | Compositions and uses thereof | |
| GB201511886D0 (en) | Uses and compositions |